Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Almac Publishes Breast Cancer Chemotherapy Response Assay

Published: Thursday, February 06, 2014
Last Updated: Wednesday, February 05, 2014
Bookmark and Share
Company announces publication of assay in the Journal of the National Cancer Institute.

Almac’s Diagnostics business unit has announced the publication of its breast cancer chemotherapy response assay in the Journal of the National Cancer Institute (JNCI).

The article entitled “Identification and Validation of an Anthracycline/Cyclophosphamide– Based Chemotherapy Response Assay in Breast Cancer” led by Almac’s Medical Director, Professor Richard Kennedy gives detail on the development and initial validation of a predictive gene signature for chemotherapy response in breast cancer.

Breast Cancer is the world’s most common cancer among women with one in eight diagnosed in their lifetime. Although modern chemotherapy reduces the risk of recurrence for some patients, not everyone benefits. At present there is no means of identifying those patients who will and will not respond to first line therapy.

Almac’s objective in the development of this assay was to provide a means of identifying those breast cancer patients more likely to respond to standard of care chemotherapy treatment.

The assay was developed by Almac in collaboration with Queens University, Belfast and the Mayo Clinic, Rochester, USA. Almac carried out microarray analysis of patient samples and identified a molecular subgroup with a deficiency in DNA damage repair, termed DDRD for DNA Damage Repair Deficient. Almac then developed a 44 gene classifier capable of prospectively identifying this molecular group in patient tumour samples.

The DDRD signature was then initially validated in a neo-adjuvant breast cancer cohort. In the neo-adjuvant setting the assay predicted complete pathologic response with an odds ratio of 3.96, meaning those patients that were DDRD positive were almost four times more likely to respond to treatment compared to patients that were DDRD negative. In the adjuvant setting, a DDRD positive result predicted 5 year relapse free survival with a Hazard Ratio 0.37 compared with test negative patients.

“The publication of this data represents a significant milestone for Almac as we transition this assay into the clinic. The publication of these results combined with our recent out-licensing of the assay to Genomic Health for use in breast cancer patients, highlights the quality of the science being carried out here in Almac” said Professor Paul Harkin, President and Managing Director of Almac’s Diagnostics business unit.

The test has been developed and validated exclusively using formalin fixed paraffin embedded (FFPE) tissue using Almac’s own proprietary Breast Cancer DSA®.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Announce Launch NGS Data Analysis Services
Almac will utilize the latest sequencing technologies and most sophisticated modern computational analysis techniques to ensure optimal results from customer data.
Wednesday, February 01, 2012
Almac to Perform the Analytic Phase of AclarusDx™ for Exonhit
Exonhit AclarusDx™ is a micro-array-based test intended to aid in the diagnosis of AD by detecting biomarkers specific for AD in peripheral blood.
Tuesday, July 05, 2011
Almac Successfully Moves its Clinical Technologies Business Unit into New North American Headquarters
Almac has completed the first phase of relocating employees from three Almac business units to the new 240,000 square feet integrated drug development facility.
Thursday, October 14, 2010
Almac One Step Closer to Completion of U.S. Headquarters Buildings
The ‘Use and Occupancy’ permits confirm that the building rights are now solely under Almac ownership.
Friday, September 10, 2010
Almac Launch Biomarkers for Biopharma
Almac’s new range of solutions are developed to support biopharma companies in adopting biomarker strategies.
Tuesday, August 03, 2010
Almac’s US Headquarters will Address Capacity Demand for Clinical Supplies
Huge increase in storage capacity for ambient, cold storage and controlled drugs.
Thursday, June 24, 2010
Almac Extends Site-Specific PEGylation Technology to Single Domain Antibodies
The Company will announce the extension of its site specific PEGylation technology at BIO 2010, the annual Bio Industry Association convention.
Thursday, April 29, 2010
Almac Partners with Merck KGaA and the MRC to Assess Markers of Response to Cetuximab Therapy
Samples from COIN trial to be used to assess markers of response to cetuximab.
Thursday, April 15, 2010
Almac Partners with Merck KGaA and the MRC to Assess Markers of Response to Cetuximab Therapy
Samples from COIN trial to be used to assess markers of response to cetuximab.
Monday, April 12, 2010
Almac to Improve Label Approval Process in Clinical Trials
Almac Clinical Services continue to showcase innovative technology with the launch of their new web based clinical Label Approval System – LAS a unique workflow-based label approval management system. LAS gives users full online review, amendment, traceability and control functionality regardless of geographic location.
Thursday, April 01, 2010
Almac and Queens University Belfast showcase Northern Irish ‘oncology hub’ to senior Washington DC delegates
The event introduces the Almac led initiative to a US audience of senior pharma, academic and Governmental agencies to encourage strategic collaboration in oncology between the US and Northern Ireland.
Wednesday, March 17, 2010
Almac Expands Radiolabelling Facilities to Include 14C API and IMP Supply
Launch of new MHRA audited facility will enable Almac to meet the rapid timelines required by Pharma companies in drug development.
Friday, February 26, 2010
Bioinformatics Expansion Heralds Further Growth for Almac
Almac Diagnostics – a personalized medicine company today announced the extension of its Bioinformatics department.
Thursday, December 03, 2009
Gene Expression Study to Develop Prognostic Test for Early Non-Small Cell Lung Cancer
Almac Diagnostics has announced details of a global multi-centre collaborative lung cancer study with leading research organisations in the USA, Canada, Asia and Europe.
Thursday, September 04, 2008
Almac Diagnostics extends agreement with Affymetrix
Almac Diagnostics announces the extension and widening of its ‘Powered by Affymetrix™’ (PbA) agreement with Affymetrix Inc. for an additional 15 years.
Monday, March 03, 2008
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos